CTOs on the Move

Affigen

www.affigen.com

 
Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.affigen.com
  • 20 S. Sarah St.
    Saint Louis, MO USA 63108
  • Phone: 314.254.5081

Executives

Name Title Contact Details

Funding

Affigen raised $17M on 02/21/2017

Similar Companies

Dzeel Clinical

Dzeel Clinical is a Garner, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EcoSynthetix

EcoSynthetix is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Castle Biosciences

Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.

Exothera

Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium

Botanix Pharmaceuticals

Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.